Search

Search for a specific protein in the Platelet Interactome


(Example: vasp)

 

Advanced Search

Get detailed protein information focusing on various characteristics and extract interaction networks

 

Legend

 

About

Go Back

Description for Protein AR

androgen receptor
201 total interacting proteins; 74 platelet interacting proteins
Icon Book Platelet Evidence (proteome studies/others : 0/0)
(Not detected in platelets)
Summary:
The androgen receptor gene is more than 90 kb long and codes for a protein that has 3 major functional domains: the N-terminal domain, DNA-binding domain, and androgen-binding domain. The protein functions as a steroid-hormone activated transcription factor. Upon binding the hormone ligand, the receptor dissociates from accessory proteins, translocates into the nucleus, dimerizes, and then stimulates transcription of androgen responsive genes. This gene contains 2 polymorphic trinucleotide repeat segments that encode polyglutamine and polyglycine tracts in the N-terminal transactivation domain of its protein. Expansion of the polyglutamine tract causes spinal bulbar muscular atrophy (Kennedy disease). Mutations in this gene are also associated with complete androgen insensitivity (CAIS). Two alternatively spliced variants encoding distinct isoforms have been described. [provided by RefSeq] (PubMed Links)
Domains and Motifs:
  • CC: Coiled Coil
  • ZnF_C4: c4 zinc finger in nuclear hormone receptors
  • HOLI: Ligand binding domain of hormone receptors
    • Gene Ontology:
    Gene Ontology Annotations
    KEGG - Enzyme ID(s):
    None Available
    KEGG - Orthology:
    K08557
    KEGG - Pathway(s):
    hsa04114; hsa05200; hsa05215
    (The yellow boxes represents platelet proteins)
    Nomenclature / Alternative Names:
    Androgen receptor isoform 2; Dihydrotestosterone receptor; DHTR; KD; AIS; TFM; SBMA; NR3C4; SMAX1; HUMARA; Androgen receptor isoform 1; OTTHUMP00000061928
    Approved Symbol:
    AR
    (De-) Phosphorylations:
    Total (de-) phosphorylation sites: 33
    Human (de-) phosphorylation sites: 33; No platelet phosphorylation sites
    Phosphorylation Targets:
    Total phosphorylation targets: 0
    Human phosphorylation targets: 0;Predicted platelet targets: 0
    		Protein Characteristics:
    Isoform-specific Information
    Icon DrugsAssociated Drugs (DrugBank Accession):

  • (2r)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-3-[(4-Fluorophenyl)Sulfonyl]-2-Hydroxy-2-Methylpropanamide(db);
  • (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide(db);
  • (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide(db);
  • (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide(db);
  • (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide(db);
  • (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE(db);
  • (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE(db);
  • (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE(db);
  • 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE(db);
  • 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE(db);
  • 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE(db);
  • 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile(db);
  • 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL(db);
  • 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE(db);
  • 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile(db);
  • 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE(db);
  • 9alpha-Fluorocortisol(db);
  • Bicalutamide(db);
  • Boldenone(db);
  • Calusterone(db);
  • Cyproterone(db);
  • Danazol(db);
  • Delta1-dihydrotestosterone(db);
  • Dihydrotestosterone(db);
  • Dromostanolone(db);
  • Drospirenone(db);
  • Flufenamic Acid(db);
  • Fluoxymesterone(db);
  • Flutamide(db);
  • Levonorgestrel(db);
  • Methyltestosterone(db);
  • Methyltrienolone(db);
  • Nandrolone decanoate(db);
  • Nandrolone phenpropionate(db);
  • Nilutamide(db);
  • Oxandrolone(db);
  • S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE(db);
  • Spironolactone(db);
  • Testosterone(db);
  • Testosterone Propionate(db)

    Associated Genetic Diseases:

  • Androgen insensitivity syndrome(Pd);
  • Androgen insensitivity, complete(Pd);
  • Androgen insensitivity, partial(Pd);
  • Breast cancer, male, with reifenstein syndrome(Pd);
  • Hypospadias, isolated distal penile shaft(Pd);
  • Hypospadias, perineal(Pd);
  • Prostate cancer(Pd);
  • Prostate cancer susceptibility(Pd);
  • Spinal and bulbar muscular atrophy, X-linked(Pd)
    		• Predicted Transmembrane Domains:
  • Isoform 2 : 0
  • Isoform 1 : 0
    • Additional Identifiers:

    HPRD: 02437 Entrez Gene ID: 367 OMIM ID: 313700 Swissprot Accession: P10275; Q9NUA2;